Results 231 to 240 of about 284,370 (314)

Artificial Intelligence Model’s assessment of intra-sample heterogeneity of HER2 IHC in breast cancer is related to interobserver and intraobserver agreement among pathologists

Ferrari PSSM, de Macedo MP, Cunha IWd, Giongo AA, Camacho AHdS, Souza AG, Rodrigues ALdB, Karlinski ÂG, Mercante AMdC, Monnerat ALC, Verdolin AA, Castro AAOL, Nicolli AC, Volpato AHC, Garibaldi BNdA, Santos CdC, Klock C, Saggioro FP, Tiburzio G, Monteiro GBM, Maximiano GNT, Vignal GM, Silva ICd, Nagel J, de Rezende LMMC, Neder L, Matushita MAM, Gaglionone NC, Barreto PSD, Peixoto RBP, Soares FA.   +30 more
europepmc   +1 more source

Research on Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Therapy in cN1 Breast Cancer Patients. [PDF]

Cancer Med
Shang J, Chen J, Zheng R, Huang Z, Wu X, Min J, Chen M, Quan Y, Wu B, Zuo H, Fu H, Wan Y, Bai J, Pan G.   +13 more
europepmc   +1 more source

RNA‐binding protein RBMS1: A new target for cancer diagnosis and treatment

Precision Medical Sciences, EarlyView.
This schematic illustrates the diverse regulatory roles of RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) across multiple human cancers. In breast cancer, RBMS1 stabilizes B4GALT1 mRNA to promote PD‐L1 glycosylation, modulating tumor immune escape and immunotherapy efficacy.
Xingda Run, Shiwei Jiang, Kun Xu, Yu Fan, Yanwen Chen, Ziao Liu, Zengli Miao, Wei Tian   +7 more
wiley   +1 more source

Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer. [PDF]

Breast Cancer Res Treat
Song PN, Mansur A, Gallegos CA, Ghanate P, Lapi SE, Sorace AG.   +5 more
europepmc   +1 more source

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials [PDF]

, 2017
et al,, Mutch, David G
core   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Trastuzumab deruxtecan in advanced breast cancer: a real-world study of efficacy and safety in Chinese cohort with HER2-positive and HER2-low expression. [PDF]

Front Oncol
Liang H, Zhu Z, Kong F.
europepmc   +1 more source

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Precision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song, Lei Wang, Guopeng Zhao, Song Tan, Xin Liu, Xinghua Li   +5 more
wiley   +1 more source

Combining radiotherapy with CAR‐T cell therapy for solid tumors: Challenges, mechanisms, and future directions

Precision Radiation Oncology, EarlyView.
Radiotherapy enhances CAR‐Tcell therapy by increasing antigenicity, improving trafficking, and reshaping the tumor microenvironment. Despite its dual effects, including potential immune suppression, understanding these mechanisms enables the development of strategies to maximize synergy in solid tumors.
Leran Qiu, Xingyu Zhou, Jiao Xue, Xiaokang Zhang, Songbing Qin   +4 more
wiley   +1 more source

Boron‐10 carriers and their applications in boron neutron capture therapy

Precision Radiation Oncology, EarlyView.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
wiley   +1 more source